Laverock Therapeutics
Laverock Therapeutics, established in 2021 to commercialise a gene editing induced gene silencing (GEiGS) platform for all human therapeutic applications
Stevenage, UKwww.laverocktx.com ↗
Total raised
€26M
€25,689,474
Funding rounds
3
Investors
9
distinct backers
Active since
2023-10
latest 2026-06
Funding by year
EUR raised per year · 2026 YTDSignals
Medium confidenceRaise-next likelihood27
base rate 46% for Grant
- ▼ Raised very recently
- ▼ Down/flat last round
Exit likelihood14
base rate 12% (2+ rounds)
- ▲ 3 rounds raised
Timing: too soon vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-06-01 | Grant | €2.5M | — | View deal → |
| 2025-06-30 | Seed | €7.6M | Calculus Capital,Eli lilly and company,Eos Advisory,Maven Capital Partners,Mercia Ventures,Norcliffe Capital | View deal → |
| 2023-10-02 | Seed | €16M | Calculus Capital,Eli lilly and company,EOS Ventures,Maven Capital Partners,Mercia Ventures,Tekfen Ventures+1 more | View deal → |